Journal article
Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy
WB Dyer, JCG Tan, T Day, L Kiers, MC Kiernan, C Yiannikas, S Reddel, K Ng, P Mondy, PM Dennington, MM Dean, HM Trist, C dos Remedios, PM Hogarth, S Vucic, DO Irving
Brain and Behavior | WILEY | Published : 2016
DOI: 10.1002/brb3.516
Abstract
Objective: The objective of the study was to profile leukocyte markers modulated during intravenous immunoglobulin (IVIg) treatment, and to identify markers and immune pathways associated with clinical efficacy of IVIg for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) with potential for monitoring treatment efficacy. Methods: Response to IVIg treatment in newly diagnosed IVIg-naïve and established IVIg-experienced patients was assessed by changes in expression of inflammatory leukocyte markers by flow cytometry. The adjusted INCAT disability and Medical Research Council sum scores defined clinical response. Results: Intravenous immunoglobulin modulated immunopathogenic pat..
View full abstractGrants
Funding Acknowledgements
The study was funded by the Australian Red Cross Blood Service. The Australian Government funds the Australian Red Cross Blood Service to provide blood, blood products, and services to the Australian community.